Home > Insider Trading > Filing (0001144204-13-045323)

Filing Details

Accession Number:: 0001144204-13-045323
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-08-13 21:30:55
Reporting Period:: 2013-08-09

Filing Date:: 2013-08-13
Accepted Time:: 2013-08-13 21:30:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1270073	Intercept Pharmaceuticals Inc	ICPT	Pharmaceutical Preparations (2834)	223868459

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1559537	Paolo Fundaro	C/O Intercept Pharmaceuticals, Inc. 18 Desbrosses Street New York NY 10013		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-08-09	325	$0.00	2,628	No	4	M	Direct
Common Stock	Acquisiton	2013-08-12	3,461	$10.11	6,089	No	4	M	Direct
Common Stock	Disposition	2013-08-12	800	$45.89	5,289	No	4	S	Direct
Common Stock	Disposition	2013-08-12	3,959	$46.18	1,330	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2013-08-09	325	$0.00	325	$0.00
Common Stock	Options to Purchase Common Stock	Disposition	2013-08-12	3,461	$0.00	3,461	$10.11

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,298			No	4	M	Direct
0		2017-03-23	No	4	M	Direct

Footnotes

Conversion of restricted stock units ("RSUs") to shares of common stock on a one-for-one basis.
On November 16, 2012, the reporting person was granted 2,596 RSUs. The RSUs reported as having been disposed and the corresponding shares reported as having been acquired, representing 12.5% of the shares underlying the RSUs, became vested on August 9, 2013, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remainder of the shares underlying the RSUs will vest pro rata on every subsequent three-month anniversary of such date through August 9, 2014, subject to the terms and conditions of the award and the 2012 Plan.
The shares of common stock underlying this option are fully vested.
The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 28, 2013.
This transaction was executed in multiple trades at prices ranging from $44.99 to $45.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $45.995 to $46.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.